Gallein but not fluorescein enhances the PGD-stimulated synthesis of osteoprotegerin and interleukin-6 in osteoblasts: Amplification of osteoprotegerin/interleukin-6 by gallein.

Prostaglandins Leukot Essent Fatty Acids

Department of Pharmacology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan; Department of Metabolic Research, Research Institute, National Center for Geriatrics and Gerontology, Obu 474-8511, Japan; Department of Clinical Laboratory, Hospital, National Center for Geriatrics and Gerontology, Obu 474-8511, Japan. Electronic address:

Published: April 2024

AI Article Synopsis

  • Gallein is a small molecule that inhibits Gβγ subunits, showing promise as a potential treatment for inflammation-related organ dysfunctions, though its effects on bone metabolism are not yet clear.
  • Prostaglandins, like PGD, are crucial for bone health, and they induce the production of important factors like osteoprotegerin (OPG) and interleukin-6 (IL-6) in osteoblasts, influenced by specific signaling pathways.
  • In this study, gallein was found to enhance the release of OPG and IL-6 when cells were stimulated with PGD, acting specifically on Gβγ subunits without affecting the activation of key signaling proteins like p38 MAPK or JNK.

Article Abstract

Gallein, a small molecule related to fluorescein, is established as an inhibitor of Gβγ subunits to inhibit G protein (Gs) signaling. This agent is providing a potential therapeutic strategy to ameliorate organ dysfunctions especially involved in inflammation, however; the effects on bone metabolism have not yet been clarified. Prostaglandins (PGs) play important roles as autacoids including osteoblasts, and d-type prostanoid (DP) receptor, a member of G protein-coupled receptor specific to PGD, is expressed on osteoblasts. We previously reported that prostaglandin D (PGD) induces the syntheses of osteoprotegerin (OPG) and interleukin-6 (IL-6), essential factors in bone remodelling process, and p38 mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK), and p44/p42 MAPK are involved in the signal transduction of PGD in osteoblast-like MC3T3-E1 cells. Thus, we investigated in this study that the effect and the underlying mechanism of gallein, an inhibitor Gβɤ subunits, on the syntheses of OPG and IL-6 induced by PGD in these cells. The cultured cells were treated with gallein or fluorescein, a structurally related compound inactive to Gβɤ subunits, and subsequently stimulated with PGD. Not fluorescein but gallein amplified the PGD-stimulated releases of OPG and IL-6. Gallein enhanced the PGD-upregulated mRNA expression levels of OPG and IL-6. Regarding the signaling mechanism, gallein did not affect the PGD-induced phosphorylation of p38 MAPK, JNK, or p42 MAPK. In conclusion, gallein upregulates the PGD-stimulated syntheses of OPG and IL-6 by the specific effect to inhibit Gβγ subunits in osteoblasts, but the effect is not exerted at the upstream of p38 MAPK, JNK, or p44/p42 MAPK activation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.plefa.2024.102639DOI Listing

Publication Analysis

Top Keywords

opg il-6
16
gallein
9
gallein fluorescein
8
gβγ subunits
8
jnk p44/p42
8
p44/p42 mapk
8
mechanism gallein
8
gβɤ subunits
8
syntheses opg
8
p38 mapk
8

Similar Publications

Background: Castration of adult male rats led to the development of osteoporosis. Oxidative stress and inflammatory factors have been identified as potential causative factors. Notably, oxymatrine (OMT) possesses potent anti-inflammatory and antioxidant activities.

View Article and Find Full Text PDF

Bone is a common and debilitating site for metastatic cancer cell expansion. Skeletal metastasis is a multistage process, with primary stages of circulating tumour cells, progressing to a dormant state in vasculature and bone marrow niches, followed by tumorigenic reactivation, proliferation, and finally bone destruction. The frequency of bone metastasis is reconciled in Paget's "seed and soil" hypothesis, where a conducive microenvironment (bone niche) is essential for cancer cell colonisation.

View Article and Find Full Text PDF

Are the Soluble Receptors sRAGE, sRANKL, and Osteoprotegerin Associated with Anemia in Rheumatoid Arthritis?

Int J Mol Sci

November 2024

Department of Medical Biochemistry, Faculty of Pharmacy, Medical University of Plovdiv, 15A Vasil Aprilov Blvd., 4002 Plovdiv, Bulgaria.

Article Synopsis
  • Rheumatoid arthritis (RA) is an autoimmune disease that can cause inflammation and lead to anemia, and this study explores how certain soluble receptors are affected in different RA patient subgroups based on anemia types and iron levels.
  • The findings show higher levels of sRAGE and sRANKL in patients with anemia of chronic disease combined with iron deficiency anemia (ACD/IDA), while OPG levels decreased, indicating potential differences in disease effects between anemia types.
  • The study concludes that soluble receptors like sRAGE, sRANKL, and OPG could serve as biomarkers in RA patients, helping to identify those at risk for anemia and better understand the condition's progression.
View Article and Find Full Text PDF

Gallein is a known Gβγ subunit inhibitor, but its function in bone metabolism, especially in osteoblasts, and its molecular mechanism remains to be elucidated. Osteoprotegerin (OPG), which is secreted from osteoblasts, binds to nuclear factor kB receptor activator (RANK) ligand (RANKL) as a decoy receptor, prevents RANKL-RANK binding, and inhibits bone resorption. IL-6 is not only a bone resorption factor but also as a bone metabolism regulator.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate the clinical and radiographic factors, along with salivary levels of specific biomarkers, in patients with type-II diabetes mellitus (T2DM) receiving different types of dental implants.
  • It involved four groups of participants with varying conditions (T2DM and non-T2DM) and types of implants (standard and short dental implants), focusing on their periodontal health and salivary cytokine levels.
  • Results showed that T2DM patients had worse periodontal conditions compared to non-T2DM patients, demonstrating higher plaque index scores and other unfavorable clinical metrics over time.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!